loader2
Partner With Us NRI

Morepen Laboratories Ltd share Price Today

Company details

51.87
56.38
27.55
56.40
6M Return 25.97%
1Y Return 102.97%
Mkt Cap.(Cr) 2,868.68
Volume 35,376,754
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 35,376,754

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Morepen Laboratories announced Q4FY24 & FY24 results:

  • Q4FY24 Revenue: Gross revenue of Rs 427 crore, 16.5% increase from Rs 367 crore in Q4’FY23.
  • Annual FY24 Revenue: Rs 1,704 crore, a notable 20% rise compared to Rs 1,424 crore in FY23.
  • EBITDA: EBITDA for Q4FY24 surged by 182% to Rs 52.62 crore from Rs 18.68 crore in the same quarter last year. For the full fiscal year, EBITDA more than doubled, achieving Rs 172.60 crore, up 101% from Rs 85.67 crore in FY23.
  • Profit Before Tax (PBT): PBT for Q4FY24 was Rs 42.20 crore, a substantial increase of 279% from Rs 11.14 crore in Q4FY23. Annually, PBT grew by 143% to Rs 135.42 crore from Rs 55.76 crore in FY23.
  • Profit After Tax (PAT): The PAT for Q4FY24 stood at Rs 28.74 crore, showing a 249% growth compared to Rs 8.24 crore in the same period last year. On an annual basis, PAT increased by 150% to Rs 96.62 crore from Rs 38.68 crore in FY23.
  • Earnings Per Share (EPS): Jumped from Rs 0.77 to Rs 1.88 for FY24, indicating a great start to the journey ahead.

Sushil Suri, Chairman and Managing Director of Morepen Laboratories, commented on the results, stating, "We are excited with the robust performance across all segments. Our strategic investments in the medical devices and API businesses have yielded excellent results, and we are confident of sustaining this momentum. The future looks promising as we continue to increase capacities and expand our market reach."

Result PDF

View Other Company Results

Morepen Laboratories Ltd shares SWOT Analysis

Strengths (10)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth

Weakness (1)

  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (3)

  • Highest Recovery from 52 Week Low
  • RSI indicating price strength
  • High Volume, High Gain

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 57.7
R2 59.3
R3 62.2
Pivot

54.79

S1 53.2
S2 50.3
S3 48.7
EMA SMA
49.0
48.1
47.2
44.3
48.5
48.2
48.1
44.5
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
HRTI PRIVATE LIMITED Bulk Purchase 2024-06-14 55.12 3882876 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-06-14 55.16 3205071 NSE
HRTI PRIVATE LIMITED Bulk Sell 2024-06-14 55.1 4683739 NSE
Name Category Shares
SUSHIL SURI PROMOTER 1.08%
ANJU SURI PROMOTER 1.01%
SONIA PANKAJ BAJAJ PROMOTER 0.72%
SANJAY SURI PROMOTER 0.67%
SUNITA SURI PROMOTER 0.62%
VARUN SURI PROMOTER 0.6%
MAMTA SURI PROMOTER 0.59%
SCOPE CREDITS AND FINANCIAL SERVICES PVT. LTD. PROMOTER 3.05%
CONCEPT CREDITS AND CONSULTANTS PVT. LTD. PROMOTER 3%
BROOK INVESTMENTS AND FINANCIAL SERVICES PVT. LTD. PROMOTER 2.97%
SOLITARY INVESTMENTS AND FINANCIAL SERVICES PVT. LTD. PROMOTER 2.96%
SOLACE INVESTMENTS AND FINANCIAL SERVICES PVT. LTD. PROMOTER 2.95%
MID MED FINANCIAL SERVICES AND INVESTMENTS PVT. LTD. PROMOTER 2.93%
REACT INVESTMENTS AND FINANCIAL SERVICES PVT. LTD. PROMOTER 2.92%
EPITOME HOLDINGS PVT.LTD. PROMOTER 2.84%
SEED SECURITIES AND SERVICES PVT. LTD. PROMOTER 2.8%
SQUARE INVESTMENTS AND FINANCIAL SERVICES PVT. LTD. PROMOTER 2.76%
LIQUID HOLDINGS PVT. LTD. PROMOTER 0.98%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Morepen Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Morepen Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 56.12 1,516.00 1,564.75 4,588.60 1,109.55
% Change 7.82 0.34 1.31 -0.11 1.75
Mcap Cr 2,868.68 363,739.19 126,332.75 121,813.11 111,646.69
Revenue TTM Cr 1,417.53 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 38.68 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 29.84 36.34 29.68 76.10 28.94
1 Year Return 102.97 53.43 59.42 31.57 114.34
ROCE 21.70 16.79 14.76 19.30 16.25
ROE 20.27 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 752.91 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,088.77 -1,030.79
LAST 3M 113,155.52 -39,495.50
LAST 6M 184,812.44 -13,263.60
LAST 12M 291,038.85 99,015.20

Morepen Laboratories Ltd Information

Stock PE (TTM)
29.84
Promoter Holding
38.22%
Book Value
16.5744
ROCE
21.7%
ROE
20.27%
Description
  • Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre. The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride. During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT. During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency. During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products. During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA`s for the molecule. During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S. During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand "Dr. Morepen". During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment. In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many anti-diabetic molecules. The Company launched `IntebactImun` in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023.

Registered Address

Morepen Village, Nalagarh Road Near Baddi, Solan, Himachal Pradesh, 173205

Tel : 91-01795-276201-03
Email : investors:morepen.com
Website : http://www.morepen.com
Registrar

Mas Services Limited

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500288
NSE Code : MOREPENLAB
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE083A01026

FAQ’s on Morepen Laboratories Ltd Shares

You can buy Morepen Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Morepen Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:59 PM the closing price of Morepen Laboratories Ltd was Rs.56.12.

The latest PE ratio of Morepen Laboratories Ltd as of Jun 14, 2024 03:59 PM is 29.84

The latest PB ratio of Morepen Laboratories Ltd as of Jun 14, 2024 03:59 PM is 0.30

The 52-week high of Morepen Laboratories Ltd share price is Rs. 56.40 while the 52-week low is Rs. 27.55

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:59 PM, the market cap of Morepen Laboratories Ltd stood at Rs. 2,868.68.

Download App

Download Our App

Play Store App Store
market app